Comparative effect of cisplatin, spiroplatin, carboplatin and iproplatin in a human tumor clonogenic assay View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1990-07

AUTHORS

Wilfried Schroyens, Pierre Dodion, Marcel Rozencweig

ABSTRACT

A modified double-layer Hamburger and Salmon cloning assay was used to test cisplatin and its analogs (spiroplatin, carboplatin and iproplatin) on fresh tumor samples from 63 patients with a variety of non-hematological malignancies. Among them were 18 breast cancers, 17 ovarian cancers and 7 of unknown primaries. Half the patients received prior chemotherapy. Cisplatin regimens were given in 16 cases. When possible, cells were exposed for 1 h to each drug in concentrations of 0.1 Μg/ml and 1.0 Μg/ml for cisplatin and spiroplatin, 1.0 Μg/ml and 10 Μg/ml for carboplatin and iproplatin. A ≧50% cell kill with at least one drug was found in 20 samples including 8 ovarian cancers, 3 breast cancers and 1 unknown primary. A ≧70% cell kill was seen in 2 samples with cisplatin, 3 with spiroplatin and carboplatin, and 6 with iproplatin. There was only partial cross-resistance between cisplatin and its analogs. Among 57 paired comparisons of cisplatin with spiroplatin, 2 showed drug sensitivity to cisplatin alone, 6 to spiroplatin alone, and 6 to both. The same sort of observation was made with carboplatin. The lack of cross-resistance between cisplatin and iproplatin was particularly striking: among 53 pairs, 6 were sensitive to cisplatin alone, 8 to iproplatin alone, and 2 to both. About 20% of the samples that were resistant to cisplatin were sensitive to iproplatin. Our data show hints of activity in breast and ovarian cancers with all analogs and suggest that they will achieve clinical antitumor activity similar to that they will achieve clinical antitumor activity similar to that of cisplatin. The in vitro evidence of incomplete cross-resistance between cisplatin and its analogs should be investigated further. More... »

PAGES

392-396

References to SciGraph publications

  • 1984-09. Phase II study of carminomycin in a human tumor cloning assay in INVESTIGATIONAL NEW DRUGS
  • 1984. Clinical Experience with 1, 1-Diaminomethylcyclohexane (Sulphato) Platinum (II) (TNO-6) in PLATINUM COORDINATION COMPLEXES IN CANCER CHEMOTHERAPY
  • 1989-11. Cisplatin/carboplatin cross-resistance in ovarian cancer in BRITISH JOURNAL OF CANCER
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/bf01612923

    DOI

    http://dx.doi.org/10.1007/bf01612923

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1038270434

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/2202731


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Carboplatin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cisplatin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Screening Assays, Antitumor", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Organoplatinum Compounds", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Service de M\u00e9decine et Laboratoire d'Investigation Clinique H.J. Tagnon, Institut Jules Bordet, Centre des Tumeurs, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium", 
              "id": "http://www.grid.ac/institutes/grid.4989.c", 
              "name": [
                "Service de M\u00e9decine et Laboratoire d'Investigation Clinique H.J. Tagnon, Institut Jules Bordet, Centre des Tumeurs, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Schroyens", 
            "givenName": "Wilfried", 
            "id": "sg:person.0653223122.50", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653223122.50"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Service de M\u00e9decine et Laboratoire d'Investigation Clinique H.J. Tagnon, Institut Jules Bordet, Centre des Tumeurs, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium", 
              "id": "http://www.grid.ac/institutes/grid.4989.c", 
              "name": [
                "Service de M\u00e9decine et Laboratoire d'Investigation Clinique H.J. Tagnon, Institut Jules Bordet, Centre des Tumeurs, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Dodion", 
            "givenName": "Pierre", 
            "id": "sg:person.01337475021.81", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01337475021.81"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Pharmaceutical Research and Developement Division, Bristol-Myers Company, Wallingford, Conn., USA", 
              "id": "http://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Pharmaceutical Research and Developement Division, Bristol-Myers Company, Wallingford, Conn., USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Rozencweig", 
            "givenName": "Marcel", 
            "id": "sg:person.01017660713.13", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017660713.13"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/bjc.1989.356", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017924009", 
              "https://doi.org/10.1038/bjc.1989.356"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00175375", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041335420", 
              "https://doi.org/10.1007/bf00175375"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-1-4613-2837-7_27", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018362607", 
              "https://doi.org/10.1007/978-1-4613-2837-7_27"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1990-07", 
        "datePublishedReg": "1990-07-01", 
        "description": "A modified double-layer Hamburger and Salmon cloning assay was used to test cisplatin and its analogs (spiroplatin, carboplatin and iproplatin) on fresh tumor samples from 63 patients with a variety of non-hematological malignancies. Among them were 18 breast cancers, 17 ovarian cancers and 7 of unknown primaries. Half the patients received prior chemotherapy. Cisplatin regimens were given in 16 cases. When possible, cells were exposed for 1 h to each drug in concentrations of 0.1 \u039cg/ml and 1.0 \u039cg/ml for cisplatin and spiroplatin, 1.0 \u039cg/ml and 10 \u039cg/ml for carboplatin and iproplatin. A \u226750% cell kill with at least one drug was found in 20 samples including 8 ovarian cancers, 3 breast cancers and 1 unknown primary. A \u226770% cell kill was seen in 2 samples with cisplatin, 3 with spiroplatin and carboplatin, and 6 with iproplatin. There was only partial cross-resistance between cisplatin and its analogs. Among 57 paired comparisons of cisplatin with spiroplatin, 2 showed drug sensitivity to cisplatin alone, 6 to spiroplatin alone, and 6 to both. The same sort of observation was made with carboplatin. The lack of cross-resistance between cisplatin and iproplatin was particularly striking: among 53 pairs, 6 were sensitive to cisplatin alone, 8 to iproplatin alone, and 2 to both. About 20% of the samples that were resistant to cisplatin were sensitive to iproplatin. Our data show hints of activity in breast and ovarian cancers with all analogs and suggest that they will achieve clinical antitumor activity similar to that they will achieve clinical antitumor activity similar to that of cisplatin. The in vitro evidence of incomplete cross-resistance between cisplatin and its analogs should be investigated further.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/bf01612923", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1313647", 
            "issn": [
              "0171-5216", 
              "1432-1335"
            ], 
            "name": "Journal of Cancer Research and Clinical Oncology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "4", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "116"
          }
        ], 
        "keywords": [
          "clinical antitumor activity", 
          "ovarian cancer", 
          "unknown primary", 
          "breast cancer", 
          "cell kill", 
          "antitumor activity", 
          "non-hematological malignancies", 
          "Comparison of cisplatin", 
          "fresh tumor samples", 
          "human tumor clonogenic", 
          "hints of activity", 
          "prior chemotherapy", 
          "cisplatin regimens", 
          "carboplatin", 
          "tumor samples", 
          "cancer", 
          "drug sensitivity", 
          "cisplatin", 
          "iproplatin", 
          "Comparative effects", 
          "patients", 
          "spiroplatin", 
          "drugs", 
          "primary", 
          "regimens", 
          "chemotherapy", 
          "malignancy", 
          "breast", 
          "activity", 
          "clonogenic", 
          "kill", 
          "analogues", 
          "cells", 
          "samples", 
          "evidence", 
          "cases", 
          "hamburgers", 
          "sensitivity", 
          "lack", 
          "effect", 
          "concentration", 
          "data", 
          "comparison", 
          "variety", 
          "cloning", 
          "observations", 
          "hints", 
          "pairs", 
          "same sort", 
          "sort"
        ], 
        "name": "Comparative effect of cisplatin, spiroplatin, carboplatin and iproplatin in a human tumor clonogenic assay", 
        "pagination": "392-396", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1038270434"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/bf01612923"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "2202731"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/bf01612923", 
          "https://app.dimensions.ai/details/publication/pub.1038270434"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-12-01T06:21", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_259.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/bf01612923"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf01612923'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf01612923'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf01612923'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf01612923'


     

    This table displays all metadata directly associated to this object as RDF triples.

    160 TRIPLES      21 PREDICATES      84 URIs      73 LITERALS      12 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/bf01612923 schema:about N0263586285004fa4a2c8abc5aed8e3b6
    2 N35d5f06c1630440d90f40c3b59cec343
    3 N5b511503df784cb4ab5bd8f062f3a7cb
    4 Nabde61358bb542e69be1a6fc0bf1edd0
    5 Nbb5f8219c80641b387cfdf56245cafb2
    6 anzsrc-for:11
    7 anzsrc-for:1112
    8 schema:author N94301afe75144d458692602491156e82
    9 schema:citation sg:pub.10.1007/978-1-4613-2837-7_27
    10 sg:pub.10.1007/bf00175375
    11 sg:pub.10.1038/bjc.1989.356
    12 schema:datePublished 1990-07
    13 schema:datePublishedReg 1990-07-01
    14 schema:description A modified double-layer Hamburger and Salmon cloning assay was used to test cisplatin and its analogs (spiroplatin, carboplatin and iproplatin) on fresh tumor samples from 63 patients with a variety of non-hematological malignancies. Among them were 18 breast cancers, 17 ovarian cancers and 7 of unknown primaries. Half the patients received prior chemotherapy. Cisplatin regimens were given in 16 cases. When possible, cells were exposed for 1 h to each drug in concentrations of 0.1 Μg/ml and 1.0 Μg/ml for cisplatin and spiroplatin, 1.0 Μg/ml and 10 Μg/ml for carboplatin and iproplatin. A ≧50% cell kill with at least one drug was found in 20 samples including 8 ovarian cancers, 3 breast cancers and 1 unknown primary. A ≧70% cell kill was seen in 2 samples with cisplatin, 3 with spiroplatin and carboplatin, and 6 with iproplatin. There was only partial cross-resistance between cisplatin and its analogs. Among 57 paired comparisons of cisplatin with spiroplatin, 2 showed drug sensitivity to cisplatin alone, 6 to spiroplatin alone, and 6 to both. The same sort of observation was made with carboplatin. The lack of cross-resistance between cisplatin and iproplatin was particularly striking: among 53 pairs, 6 were sensitive to cisplatin alone, 8 to iproplatin alone, and 2 to both. About 20% of the samples that were resistant to cisplatin were sensitive to iproplatin. Our data show hints of activity in breast and ovarian cancers with all analogs and suggest that they will achieve clinical antitumor activity similar to that they will achieve clinical antitumor activity similar to that of cisplatin. The in vitro evidence of incomplete cross-resistance between cisplatin and its analogs should be investigated further.
    15 schema:genre article
    16 schema:isAccessibleForFree false
    17 schema:isPartOf N82c69c812e4443afafe9affc0df9c43f
    18 Nebf9e1725cce461cae6d731b1f008978
    19 sg:journal.1313647
    20 schema:keywords Comparative effects
    21 Comparison of cisplatin
    22 activity
    23 analogues
    24 antitumor activity
    25 breast
    26 breast cancer
    27 cancer
    28 carboplatin
    29 cases
    30 cell kill
    31 cells
    32 chemotherapy
    33 cisplatin
    34 cisplatin regimens
    35 clinical antitumor activity
    36 cloning
    37 clonogenic
    38 comparison
    39 concentration
    40 data
    41 drug sensitivity
    42 drugs
    43 effect
    44 evidence
    45 fresh tumor samples
    46 hamburgers
    47 hints
    48 hints of activity
    49 human tumor clonogenic
    50 iproplatin
    51 kill
    52 lack
    53 malignancy
    54 non-hematological malignancies
    55 observations
    56 ovarian cancer
    57 pairs
    58 patients
    59 primary
    60 prior chemotherapy
    61 regimens
    62 same sort
    63 samples
    64 sensitivity
    65 sort
    66 spiroplatin
    67 tumor samples
    68 unknown primary
    69 variety
    70 schema:name Comparative effect of cisplatin, spiroplatin, carboplatin and iproplatin in a human tumor clonogenic assay
    71 schema:pagination 392-396
    72 schema:productId N1f8c936cbc244ca6b16f690852e90501
    73 N327ede6fca084c529bf94d55b95bc392
    74 N845956ed97a643f6abbc771d6e1b707c
    75 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038270434
    76 https://doi.org/10.1007/bf01612923
    77 schema:sdDatePublished 2022-12-01T06:21
    78 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    79 schema:sdPublisher Nb0a9c2840cf64d9aac2e0bf69bacbe4a
    80 schema:url https://doi.org/10.1007/bf01612923
    81 sgo:license sg:explorer/license/
    82 sgo:sdDataset articles
    83 rdf:type schema:ScholarlyArticle
    84 N0263586285004fa4a2c8abc5aed8e3b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    85 schema:name Cisplatin
    86 rdf:type schema:DefinedTerm
    87 N1f8c936cbc244ca6b16f690852e90501 schema:name dimensions_id
    88 schema:value pub.1038270434
    89 rdf:type schema:PropertyValue
    90 N327ede6fca084c529bf94d55b95bc392 schema:name doi
    91 schema:value 10.1007/bf01612923
    92 rdf:type schema:PropertyValue
    93 N35d5f06c1630440d90f40c3b59cec343 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    94 schema:name Organoplatinum Compounds
    95 rdf:type schema:DefinedTerm
    96 N5b511503df784cb4ab5bd8f062f3a7cb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    97 schema:name Drug Screening Assays, Antitumor
    98 rdf:type schema:DefinedTerm
    99 N82c69c812e4443afafe9affc0df9c43f schema:volumeNumber 116
    100 rdf:type schema:PublicationVolume
    101 N845956ed97a643f6abbc771d6e1b707c schema:name pubmed_id
    102 schema:value 2202731
    103 rdf:type schema:PropertyValue
    104 N94301afe75144d458692602491156e82 rdf:first sg:person.0653223122.50
    105 rdf:rest Nc293ba5a24304addb3febcf40a7f9247
    106 Nabde61358bb542e69be1a6fc0bf1edd0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    107 schema:name Humans
    108 rdf:type schema:DefinedTerm
    109 Nb0a9c2840cf64d9aac2e0bf69bacbe4a schema:name Springer Nature - SN SciGraph project
    110 rdf:type schema:Organization
    111 Nbb5f8219c80641b387cfdf56245cafb2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    112 schema:name Carboplatin
    113 rdf:type schema:DefinedTerm
    114 Nc293ba5a24304addb3febcf40a7f9247 rdf:first sg:person.01337475021.81
    115 rdf:rest Nca4119faa1a14ff39e5b8b20a4f7e703
    116 Nca4119faa1a14ff39e5b8b20a4f7e703 rdf:first sg:person.01017660713.13
    117 rdf:rest rdf:nil
    118 Nebf9e1725cce461cae6d731b1f008978 schema:issueNumber 4
    119 rdf:type schema:PublicationIssue
    120 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    121 schema:name Medical and Health Sciences
    122 rdf:type schema:DefinedTerm
    123 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    124 schema:name Oncology and Carcinogenesis
    125 rdf:type schema:DefinedTerm
    126 sg:journal.1313647 schema:issn 0171-5216
    127 1432-1335
    128 schema:name Journal of Cancer Research and Clinical Oncology
    129 schema:publisher Springer Nature
    130 rdf:type schema:Periodical
    131 sg:person.01017660713.13 schema:affiliation grid-institutes:grid.419971.3
    132 schema:familyName Rozencweig
    133 schema:givenName Marcel
    134 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017660713.13
    135 rdf:type schema:Person
    136 sg:person.01337475021.81 schema:affiliation grid-institutes:grid.4989.c
    137 schema:familyName Dodion
    138 schema:givenName Pierre
    139 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01337475021.81
    140 rdf:type schema:Person
    141 sg:person.0653223122.50 schema:affiliation grid-institutes:grid.4989.c
    142 schema:familyName Schroyens
    143 schema:givenName Wilfried
    144 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653223122.50
    145 rdf:type schema:Person
    146 sg:pub.10.1007/978-1-4613-2837-7_27 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018362607
    147 https://doi.org/10.1007/978-1-4613-2837-7_27
    148 rdf:type schema:CreativeWork
    149 sg:pub.10.1007/bf00175375 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041335420
    150 https://doi.org/10.1007/bf00175375
    151 rdf:type schema:CreativeWork
    152 sg:pub.10.1038/bjc.1989.356 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017924009
    153 https://doi.org/10.1038/bjc.1989.356
    154 rdf:type schema:CreativeWork
    155 grid-institutes:grid.419971.3 schema:alternateName Pharmaceutical Research and Developement Division, Bristol-Myers Company, Wallingford, Conn., USA
    156 schema:name Pharmaceutical Research and Developement Division, Bristol-Myers Company, Wallingford, Conn., USA
    157 rdf:type schema:Organization
    158 grid-institutes:grid.4989.c schema:alternateName Service de Médecine et Laboratoire d'Investigation Clinique H.J. Tagnon, Institut Jules Bordet, Centre des Tumeurs, Université Libre de Bruxelles, Brussels, Belgium
    159 schema:name Service de Médecine et Laboratoire d'Investigation Clinique H.J. Tagnon, Institut Jules Bordet, Centre des Tumeurs, Université Libre de Bruxelles, Brussels, Belgium
    160 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...